archive-com.com » COM » O » ONCGNOSTICS.COM

Total: 361

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • What is GynTect doing? | oncgnostics GmbH
    epigenetic change can be detected by specific methods in diagnostic laboratories GynTect allows the easy and reliable detection of methylated biomarkers in smears from the cervix Methylation of the GynTect markers especially occurs in cervical cancer or its precancerous lesions but not in healthy cervical tissue Therefore GynTect may contribute to the clarification of the question if a tissue alteration already requiring treatment is present This may help avoiding many surgeries Methylation occurs at certain positions of the DNA red labels in the upper part of the image during carcinogenesis Information for patients Cervical cancer Cervical cancer diagnostics What is GynTect doing More information Contact FAQ patients Information for physicians GynTect test procedure Screening algorithm Trial data FAQ physicians Order Information for diagnostic laboratories Test principle Screening algorithm Trial data FAQ Labs Order Recent Posts Greiner Bio One starts international marketing of the cervical cancer triage test GynTect oncgnostics and Greiner Bio One Diagnostics sign Partnership Agreement Fast and reliable results in cancer diagnostics Biotech startup oncgnostics receives CE mark for cervical cancer test GynTect Stay informed Enter your email address to subscribe to this blog and receive notifications of new posts by email Enter your Email Adress Our Topics

    Original URL path: http://www.oncgnostics.com/gyntect-cervical-cancer/information-for-patients/what-is-gyntect-doing/?lang=en (2016-02-15)
    Open archived version from archive

  • More information | oncgnostics GmbH
    or contact us directly Your gynecologist takes a normal smear from the cervix He she sends the smear to either his diagnostic lab or directly to oncgnostics and receives the result which he she then discusses with you GynTect gives clarity Women tested GynTect negative don t have to get surgery instead testing for HPV after 6 months should demonstrate if the infection is already cleared Women tested GynTect positive should attend a specialized colposcopy clinic where the disease is specifically localized and removed by surgery Download Flyer for physicians diagnostic labs Information for patients Cervical cancer Cervical cancer diagnostics What is GynTect doing More information Contact FAQ patients Information for physicians GynTect test procedure Screening algorithm Trial data FAQ physicians Order Information for diagnostic laboratories Test principle Screening algorithm Trial data FAQ Labs Order Recent Posts Greiner Bio One starts international marketing of the cervical cancer triage test GynTect oncgnostics and Greiner Bio One Diagnostics sign Partnership Agreement Fast and reliable results in cancer diagnostics Biotech startup oncgnostics receives CE mark for cervical cancer test GynTect Stay informed Enter your email address to subscribe to this blog and receive notifications of new posts by email Enter your Email Adress

    Original URL path: http://www.oncgnostics.com/gyntect-cervical-cancer/information-for-patients/more-information/?lang=en (2016-02-15)
    Open archived version from archive

  • FAQ patients | oncgnostics GmbH
    Index Which other diagnostic measures besides the Pap test can be performed In most European countries testing for HPV is currently not performed directly as a screening method Instead it is frequently used as a triage of women who already were diagnosed with abnormalities in the Pap test Then it is also paid by health insurances Back to Index What are low and high risk HPV types The genital HPV types are classified into two groups low and high risk HPV Low risk HPV e g 6 11 42 43 44 are almost never detected in case of a cervical cancer High risk HPV types e g 16 18 31 33 35 39 45 51 52 56 58 are detected in 99 7 of all cervical cancer cases In 70 of the cases HPV16 and HPV18 are detected Only women with long term infection with high risk HPV and subsequent cervical lesions have a risk of developing precancerous lesions and cancer It is well established nowadays that HPV infection ist he main risk factor for the development of cervical cancer Back to Index How can I get to know if I am infected with HPV HPV tests are used in order to detect an infection If the HPV test yields a negative result a precancerous lesion or even cancer can be excluded with 99 probability Only such a negative result is of high value for the patient Only a small part of the women infected with HPV will develop a cervical disease That s why we have developed GynTect which detects markers specifically occurring in precancerous and cancer cells Back to Index How can I minimize the risk of getting infected with HPV The only way to minimize the risk of getting infected by HPV is sexual abstinence Condoms offer rather good protection since HPV like other sexually transmitted diseases are transferred through exchange of body fluids It is recommended to get immunized against the two most important cancer causing strains HPV16 and HPV18 as early as possible the German STIKO now recommends immunization from the age of 9 13 But even if immunized you should continue participating in screening programs Back to Index How high is the probability to get infected with HPV Genital HPV infections occur very frequently In fact human papillomaviruses are the most frequently sexually transmitted infectous agents HPV are mainly but not exclusively transmitted sexually It is estimated that the probability to get infected with HPV ranges between 75 and 90 for both men and women Back to Index What does a positive GynTect result mean Results obtained during clinical trials indicate that upon a positive GynTect test result a severe cervical lesion a so called CIN3 or even a cervical carcinoma from a low grade CIN1 or CIN2 may develop or already be present Invasive diagnostics colposcopy and if required biopsy both in a specialized colposcopy clinic should be performed after a positive GynTect test result During this examination conspicuous surface of the cervix

    Original URL path: http://www.oncgnostics.com/gyntect-cervical-cancer/information-for-patients/faq-patients/?lang=en (2016-02-15)
    Open archived version from archive

  • Contact | oncgnostics GmbH
    oncgnostics About us Management Lab team Advisory board History Pipeline Ovarian cancer Head and neck cancer Access Contact Press Jobs News Blog Search Contact us Name Email Subject Message Information for patients Cervical cancer Cervical cancer diagnostics What is GynTect doing More information Contact FAQ patients Information for physicians GynTect test procedure Screening algorithm Trial data FAQ physicians Order Information for diagnostic laboratories Test principle Screening algorithm Trial data FAQ Labs Order Recent Posts Greiner Bio One starts international marketing of the cervical cancer triage test GynTect oncgnostics and Greiner Bio One Diagnostics sign Partnership Agreement Fast and reliable results in cancer diagnostics Biotech startup oncgnostics receives CE mark for cervical cancer test GynTect Stay informed Enter your email address to subscribe to this blog and receive notifications of new posts by email Enter your Email Adress Our Topics GynTect Cervical cancer Information for patients Information for physicians Information for diagnostic laboratories Investors contact Recent Posts Greiner Bio One starts international marketing of the cervical cancer triage test GynTect oncgnostics and Greiner Bio One Diagnostics sign Partnership Agreement Fast and reliable results in cancer diagnostics Biotech startup oncgnostics receives CE mark for cervical cancer test GynTect Show all Events Contact

    Original URL path: http://www.oncgnostics.com/gyntect-cervical-cancer/information-for-patients/contact/?lang=en (2016-02-15)
    Open archived version from archive

  • Information for physicians | oncgnostics GmbH
    in precancerous or cancer cells Thus the test allows to identify among the women with abnormal Pap smear and a positive HPV test result those who may develop or already have a dysplasia that leads to cancer New cervical cancer screening In several European countries such as the Netherlands Germany HPV testing may be used in screening of women aged 30 years and older Women with an HPV infection will then receive clarification by a suitable triage test if the infection has already led to dysplastic changes with the potential to develop cervical cancer With GynTect we provide such a triage test Information for patients Cervical cancer Cervical cancer diagnostics What is GynTect doing More information Contact FAQ patients Information for physicians GynTect test procedure Screening algorithm Trial data FAQ physicians Order Information for diagnostic laboratories Test principle Screening algorithm Trial data FAQ Labs Order Recent Posts Greiner Bio One starts international marketing of the cervical cancer triage test GynTect oncgnostics and Greiner Bio One Diagnostics sign Partnership Agreement Fast and reliable results in cancer diagnostics Biotech startup oncgnostics receives CE mark for cervical cancer test GynTect Stay informed Enter your email address to subscribe to this blog and receive

    Original URL path: http://www.oncgnostics.com/gyntect-cervical-cancer/information-for-physicians/?lang=en (2016-02-15)
    Open archived version from archive

  • Screening algorithm | oncgnostics GmbH
    with abnormal cytology findings Pap III Pap IIID those who have or develop a precancerous lesion or cancer In case of a negative GynTect result watchful waiting is recommended for the patient and to repeat the HPV test within 6 12 months in ordert o see if the infection disappears If the HPV infection remains GynTect needs to be repeated as well Click on the video below for watching this screening scheme Information for patients Cervical cancer Cervical cancer diagnostics What is GynTect doing More information Contact FAQ patients Information for physicians GynTect test procedure Screening algorithm Trial data FAQ physicians Order Information for diagnostic laboratories Test principle Screening algorithm Trial data FAQ Labs Order Recent Posts Greiner Bio One starts international marketing of the cervical cancer triage test GynTect oncgnostics and Greiner Bio One Diagnostics sign Partnership Agreement Fast and reliable results in cancer diagnostics Biotech startup oncgnostics receives CE mark for cervical cancer test GynTect Stay informed Enter your email address to subscribe to this blog and receive notifications of new posts by email Enter your Email Adress Our Topics GynTect Cervical cancer Information for patients Information for physicians Information for diagnostic laboratories Investors contact Recent Posts Greiner

    Original URL path: http://www.oncgnostics.com/gyntect-cervical-cancer/information-for-physicians/screening-algorithm/?lang=en (2016-02-15)
    Open archived version from archive

  • Trial data | oncgnostics GmbH
    In this trial all cancer cases were detected by the markers Furthermore in patients aged 30 years and older 8 of 9 CIN3 were detected by the GynTect markers This demonstrates that GynTect has a very good sensitivity for CIN3 and cancer cases Cervical cancer develops very slowly from dysplastic changes In ongoing studies we want to demonstrate if GynTect detects exactly those dysplastic lesions that have the potential to progress to carcinomas CIN Cervical Intraepithelial Neoplasia CIN 1 and CIN 2 mild to moderate dysplasia CIN 3 severe dysplasia Information for patients Cervical cancer Cervical cancer diagnostics What is GynTect doing More information Contact FAQ patients Information for physicians GynTect test procedure Screening algorithm Trial data FAQ physicians Order Information for diagnostic laboratories Test principle Screening algorithm Trial data FAQ Labs Order Recent Posts Greiner Bio One starts international marketing of the cervical cancer triage test GynTect oncgnostics and Greiner Bio One Diagnostics sign Partnership Agreement Fast and reliable results in cancer diagnostics Biotech startup oncgnostics receives CE mark for cervical cancer test GynTect Stay informed Enter your email address to subscribe to this blog and receive notifications of new posts by email Enter your Email Adress Our Topics

    Original URL path: http://www.oncgnostics.com/gyntect-cervical-cancer/information-for-physicians/trial-data/?lang=en (2016-02-15)
    Open archived version from archive

  • FAQ physicians | oncgnostics GmbH
    women with long term infection with high risk HPV and subsequent cervical lesions have a risk of developing precancerous lesions and cancer It is well established nowadays that HPV infection ist he main risk factor for the development of cervical cancer Back to Index For whom have we developed GynTect According to the already performed trials GynTect is suitable for all women who want to get further clarification after an abnormal Pap smear and or a positive HPV test if surgery is already required or if a watchful waiting strategy could demonstrate if an HPV infection and a tissue abnormality may heal without treatment Back to Index What does a positive GynTect result mean Results obtained during clinical trials indicate that upon a positive GynTect test result a severe cervical lesion a so called CIN3 or even a cervical carcinoma from a low grade CIN1 or CIN2 may develop or already be present Invasive diagnostics colposcopy and if required biopsy both in a specialized colposcopy clinic should be performed after a positive GynTect test result During this examination conspicuous surface of the cervix should be examined very thoroughly and biopsies taken during this examination should be diagnosed by histopathology In case of a negative test result a precancerous leson or cancer can almost be excluded We recommend a re examination after 6 months with HPV testing performed first Back to Index How can GynTect improve cervical cancer screening GynTect is a reliable molecular test that may clarify if a patient with unclear Pap test results Pap III PAP IIID evtl Pap IVa and or an HPV infection already has a precancerous lesion of carcinoma that requires treatment GynTect aims at the detection of specific epigenetic changes that may occur early in cervical carcinogenesis If these changes are not detectable watchful waiting may help avoiding unnecessary surgery Back to Index What are the advantages of GynTect compared to a normal cervical examination Additional tests are required in order to clarify if a precancerous lesion or cancer is the reason for an abnormal Pap smear result GynTect is an easy to perform and reliable test which detects epigenetic changes specifically occuring in cancer tissue The same cervical smear material that is currently used for Pap testing is used for GynTect Back to Index What are epigenetic markers If a normal cell develops into a tumor cell this leaves traces in the genetic material the DNA of the tumor cells Such epigenetic traces a specific methylation of certain DNA regions are detected with tests developed by oncgnostics Our studies demonstrate that the markers validated for GynTect can easily be detected in smear material from the cervix of women with disease Back to Index How much does the GynTect test cost The GynTect test which allows a better verification of the cervical cancer risk is available since 09 2015 and is thus not yet reimbursed by health insurances GynTect is performed in selected molecular diagnostics laboratories for a net price of 260 Your gynaecologist

    Original URL path: http://www.oncgnostics.com/gyntect-cervical-cancer/information-for-physicians/faq-physicians/?lang=en (2016-02-15)
    Open archived version from archive



  •